Stephen George

PharmD, MS, RPh

Senior Consultant

Tampa, FL, US

Stephen George is a pharmacist with over 30 years of experience. He has held several leadership roles within the healthcare industry. He has a successful track record directed at improving the patient experiences and outcomes. He strives for excellence with a strategic focus and strong work ethic built around integrity. Stephen has managed multi-disciplinary teams around efficiency and innovation and has delivered on top line corporate revenue growth within the healthcare market.

As a clinician he has direct patient care and management experience in a variety of settings: managed care, hospital, and clinical trials. Additionally, he has developed commercial and Part-D medical clinical programs, designed HEOR studies, audited 340‐B pricing models, and priced drugs/devices and value-based contracts.

Download bio

Loading component...

Experience

Previous positions include:

Co-owner, Conexus Health and Clinical Pharmacology Services
Pharmacy Advisor, Hillsborough County Healthcare Plan
Pharmacy Director, Physician Corporation of America
Clinical Pharmacist, Mount Carmel Medical Center (MCMC)

Publications and Presentations

Stephen has published and/or presented numerous manuscripts, abstracts, strategy sessions, and podium presentations. He has also participated as co‐investigator in several Phase II-IV clinical trials.

Professional Designations

Stephen holds a Florida pharmacist license and continues to practice in patient care.

Education

PharmD, Broadmore University
MS Hospital Pharmacy Administration, The Ohio State University
Bachelor Science Pharmacy, Samford University
Chief Administrative Pharmacy Resident, MCMC, Columbus, OH
Pharmacy Practice Resident, MCMC, Columbus, OH
Pharmacy Practice Resident, Medical University of South Carolina, Charleston

Publications

Read their latest work

Article

A claims-based analysis of prostate biopsy episodes when there is no evidence of a cancer diagnosis

26 February 2024 - by Pamela Laboy, Carol Bazell, Stephen George, Keely Congdon, Jack Tyson

Our recent analysis shows how the total cost of care for prostate biopsy episodes varied substantially, based on whether the patient had complications.

Article

Exploring Medicare Part D prior authorizations

17 June 2020 - by Stephen George, Lisa Mattie

Prior authorization presents benefits and challenges along with opportunities for improvement as plan sponsors aim to control costs and ensure access to appropriate drugs.

Article

A review of vaccinations: A tool in battling viral infections

08 June 2020 - by Stephen George, Joel Brill

In view of the COVID-19 pandemic, this paper examines why, when, and how vaccines are used; highlights the vaccine development pathway; reviews previous experience with viral pandemics; and assesses ways payers can address COVID-19.

Article

Evaluation of the Appropriateness of EmpiRx’s Clinical Savings Tracker for Estimating Ingredient Cost Savings

19 November 2019 - by Stephen George, Tracy Margiott

This report provides an independent review of the processes EmpiRx Health uses to calculate savings under the Clinical Savings Tracker component of its Clinical Care Management program.

Article

Assessing the potential revenue impact to oncology practices under a cancer drug therapy bundled reimbursement model

20 March 2017 - by Stephen George, Stuart D. Rachlin

This report evaluates the potential impact to provider reimbursement under alternative oncology payment structures and illustrates the inherent variabilities across patients using a simplified alternative oncology payment bundle for cancer drug treatments and related professional services.

Stephen George

Loading component...

Experience

Read their latest work

A claims-based analysis of prostate biopsy episodes when there is no evidence of a cancer diagnosis

Exploring Medicare Part D prior authorizations

A review of vaccinations: A tool in battling viral infections

Evaluation of the Appropriateness of EmpiRx’s Clinical Savings Tracker for Estimating Ingredient Cost Savings

Assessing the potential revenue impact to oncology practices under a cancer drug therapy bundled reimbursement model

Loading component...

CHOOSE A LOCATION AND LANGUAGE

Stephen George

Read their latest work

A claims-based analysis of prostate biopsy episodes when there is no evidence of a cancer diagnosis

Exploring Medicare Part D prior authorizations

A review of vaccinations: A tool in battling viral infections

Evaluation of the Appropriateness of EmpiRx’s Clinical Savings Tracker for Estimating Ingredient Cost Savings

Assessing the potential revenue impact to oncology practices under a cancer drug therapy bundled reimbursement model

CHOOSE A LOCATION AND LANGUAGE